Benzinga | Jan 18, 2022 08:26AM EST

I-Mab Announces First Patient Dosed In China Phase 2 Combination Trial Of Lemzoparlimab With Toripalimab In Patients With Advanced Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Jan. 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ:IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in its China phase 2 trial of lemzoparlimab in combination with the PD-1 antibody toripalimab (TUOYI(r)) in patients with advanced solid tumors. The phase 2 study is designed as a basket trial and could potentially lead to a registrational trial in China.